Study of REM-422 in Patients With AML or Higher Risk MDS

Clinical trial NCT06297941 · RECRUITING

Trial details

NCT number: NCT06297941
Sponsor: Remix Therapeutics
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Myelodysplastic Syndromes Higher Risk Myelodysplastic Syndromes Acute Myeloid Leukemia Acute Myeloid Leukemia Refractory

Start date: 2024-04-26
Primary completion: 2026-03-15
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.